Skip to content

Exploration and Establishment of an Early Warning System for Futile Reperfusion - A I S

FUtile Reperfusion in acuTe iscHEmic stRoke- FURTHER

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07045987
Enrollment
2000
Registered
2025-07-01
Start date
2025-06-01
Completion date
2029-05-31
Last updated
2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke (AIS), Endovascular Thrombectomy, Neurovascular Unit- Brain Lymphatic System

Brief summary

The goal of this prospective cohort registration study is to establish an early warning system for futile recanalization in acute ischemic stroke by analyzing multi-omics information to identify key regulatory nodes and target molecules in ineffective recanalization. The core issue addressed by this research is: Identifying key regulatory nodes and target molecules closely associated with futile recanalization, revealing the interactions among the neurovascular unit, peripheral immune cells, and the brain lymphatic system, as well as developing early diagnostic biomarkers and novel diagnostic technologies for futile recanalization.

Interventions

None listed

Sponsors

National Science and Technology Major Project
CollaboratorUNKNOWN
Xijing Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\. Aged ≥18 years 2. Acute ischemic stroke confirmed by clinical and neuroimaging criteria (CT or MRI) 3. Clinical indication for thrombectomy 4. Provision of signed informed consent

Exclusion criteria

* 1\. Preexisting dementia or severe disability (modified Rankin Scale score ≥3) 2. Cerebral vascular malformations, neoplasms, abscesses, or other significant non-ischemic brain pathologies 3. Life-limiting systemic comorbidities (e.g., end-stage organ failure, metastatic malignancies) with anticipated survival \<6 months 4. Patient or legally authorized representative declined consent 5. Anticipated poor protocol adherence or loss to follow-up

Design outcomes

Primary

MeasureTime frame
3-month mRS scoreFrom enrollment to the end of treatment at 3 months

Other

MeasureTime frame
All-cause mortality within 3 monthsFrom enrollment to the end of treatment at 3months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026